Comparison of the effects of the thrombin inhibitor r-hirudin in four animal models of neointima formation after arterial injury

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 10, 1996, Pages 1306-1311

  Gerdes, Christoph ^a   Faber Steinfeld, Verona ^a   Yalkinoglu, Özkan ^a   Wohlfeil, Stefan ^a  

^a BAYER AG   (Germany)

Author keywords

animal models; arterial injury; r hirudin; restenosis; thrombin

Indexed keywords

HIRUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; CAROTID ARTERY; DRUG EFFECT; GROWTH INHIBITION; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RABBIT; RAT; RECURRENCE RISK; RESTENOSIS; SPECIES DIFFERENCE; SWINE; THROMBOGENESIS;

EID: 0029816753     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.10.1306     Document Type: Article

References (44)

1. Ellis SG, Muller DWM. Arterial injury and the enigma of coronary restenosis. J Am Coll Cardiol 1992;19:275-277.
2. Ludbrook PA. Coronary restenosis: its mechanisms and modification. Coronary Artery Dis. 1993;4:225-228.
3. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol. 1991;17:758-769.
4. Davies MG, Hagen P-O. Pathobiology of intimal hyperplasia. Br J Surg. 1994;81:1254-1269.
5. Liu MW, Berk BC. Restenosis following coronary balloon angioplasty. Trends Cardiovasc Med. 1991;1:107-111.
6. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
7. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. N Engl J Med. 1994;330:1431-1438.
8. Lafont A, Guzman LA, Whitlow PL, Goormastic M, Cornhill JF, Chisolm GM. Restenosis after experimental angioplasty: intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res. 1995;76:996-1002.
9. Hedin U, Frebelius S, Sanchez J, Dryjski M, Swedenborg J. Antithrombin III inhibits thrombin-induced proliferation in human arterial smooth muscle cells. Arterioscler Thromb. 1994;14:254-260.
10. McNamara CA, Sarembock IJ, Gimple LW, Fenton JW, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest. 1993;91:94-98.
11. Noda-Heiny H, Sobel BE. Vascular smooth muscle cell migration mediated by thrombin and urokinase receptor. Am J Physiol. 1995;37:C1195-C1201.
12. Bachhuber BG, Sarembock IJ, Gimple LW, McNamara CA, Owens GK. Thrombin induced mitogenesis in cultured aortic smooth muscle cells requires prolonged thrombin exposure. Am J Physiol. 1995;37:C1141-C1147.
13. Vu T-KH, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
14. Nelken NA, Soifer SJ, O'Keefe J, Vu T-KH, Charo IF, Coughlin SR. Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest. 1992;90:1614-1621.
15. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Foster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
16. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Lüders S, Munz DL, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: effect of hirudin versus heparin. J Am Coll Cardiol. 1993;21:249-254.
17. Sarembock IJ, Gertz SD, Gimple LW, Owen RM, Powers ER, Roberts WC. Effectiveness of recombinant desulphatohirudin in reducing restenosis after balloon angioplasty of atherosclerotic femoral arteries in rabbits. Circulation. 1991;84:232-243.
18. Faber V, Grützmann R, Wohlfeil S, Zaiss S, Gerdes C. Balloon dilatation of pre-injured rabbit carotid arteries increases myointimal plaque formation: a valuable tool to study restenosis? Atherosclerosis. 1994;109:7. Abstract.
19. Muller DWM, Ellis SG, Topol EJ. Experimental models of coronary artery restenosis. J Am Coll Cardiol. 1992;19:418-432.
20. Jackson CL. Animal models of restenosis. Trends Cardiovasc Med. 1994;4:122-130.
21. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approach to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 1993;46:18-52 and 1993;46:249-262.
22. Herrman J-PR, Hermans WRM, Vos J, Serruys PW. Pharmacological approach to the prevention of restenosis following angioplasty: the search for the holy grail? Drugs. 1993;46:18-52 and 1993;46:249-262.
23. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M, Sigmon K, Anderson KM, Lee KL, Willerson JT on behalf of the EPIC investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet. 1994;343:881-886.
24. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig: the in vivo role of thrombin in platelet-mediated thrombosis. Circulation. 1990;82:1476-1484.
25. Bar-Shavit R, Kahn A, Wilner GD. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 1983;220:728-731.
26. Wilcox HN, Rodriguez J, Subramanian R, Ollerenshaw J, Zhong CZ, Hayzer DJ, Horaist C, Hanson SR, Lumsden A, Salam TA, Kelly AB, Harker LA, Runge M. Characterization of thrombin receptor expression during vascular lesion formation. Circ Res. 1994;75:1029-1038.
27. Ip JH, Fuster V, Israel D, Badimon L, Badimon J, Chesebro JH. The role of platelets, thrombin and hyperplasia in restenosis aftercoronary angioplasty. J Am Coll Cardiol 1991;17:77B-88B.
28. Walters TK, Gorog DA, Wood RFM. Thrombin generation following arterial injury is a critical initiating event in the pathogenesis of the proliferative stages of the atherosclerotic process. J Vasc Res. 1994;31:173-177.
29. Hatton MWC, Moar SL. Richardson M. Deendothelialization in vivo initiates a thrombogenic reaction at the rabbit aorta surface: correlation of uptake of fibrinogen and antithrombin III with thrombin generation by the exposed subendothelium. Am J Pathol. 1989;135:499-508.
30. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. P roc Natl Acad Sci U S A. 1989;86:8412-8416.
31. Jackson CL, Raines EW, Ross R, Reidy MA. Role of endogenous platelet-derived growth factor in arterial smooth muscle cell migration after, balloon catheter injury. Arterioscler Thromb. 1993;13:1218-1226.
32. Groves HM, Kinlough-Rathbone RL, Mustard JF. Development of nonthrombogenicity of injured rabbit aortas despite inhibition of platelet adherence. Arteriosclerosis- 1986;6:189-195.
33. Webster MWI, Chesebro JH, Grill DE, Badimon JJ, Badimon L, Fuster V. The thrombotic and proliferative response to angioplasty in pigs after deep arterial injury: effect of intravenous thrombin inhibition with hirudin. Circulation. 1991;84(suppl II):II-580. Abstract.
34. Unterberg C, Sandrock D, Nebendahl K, Buchwald AB. Reduced acute thrombus formation results in decreased neointimal proliferation after coronary angioplasty. J Am Coll Cardiol. 1995;26:1747-1754.
35. Ferrell M, Fuster V, Gold HK, Chesebro JH. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85:1630-1631.
36. Steele PM, Chesebro JH, Stanson AW, Holmes DR, Dewanjee MK, Badimon L, Fuster V. Balloon angioplasty: natural history of the pathophysiological response to injury in a pig model. Circ Res. 1985;57:105-112.
37. MERCATOR Study Group. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? results of the MERCATOR study: a multicenter, randomized double-blind placebo-controlled trial. Circulation. 1992;86:100-110.
38. Lam JYT, Lacoste L, Bourassa MG. Cilazapril and early atherosclerotic changes after ballon injury of porcine carotid arteries. Circulation. 1992;85:154-157.
39. Lovastatin restenosis trial study group. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med. 1994;331:1331-1337.
40. Schneider JE, Santoian EC, Gravanis MB, Ctpolla G, Anderberg K, King SB. Lovastatin fails to limit smooth muscle cell proliferation in normolipemic and hyperlipemic swine in an overstretch balloon injury model of restenosis. J Am Coll Cardiol. 1992;19:163A. Abstract.
41. Serruys PW, Herrman J-PR, Simon R, Rutsch W, Bode C, Laarman G-J, Van Dijk R, Van Den Bos AA, Umans VAWM, Fox KAA, Close P, Deckers JW for the HELVETICA investigators. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1995;333:757-763.
42. Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B for the hirulog angioplasty study investigators. Treatment with Bivalirudin (hirulog) as compared with heparin during coronary angioplasty for unstable or post-infarction angina. N Engl J Med. 1995;333:764-769.
43. Antman EM. Hirudin in acute myocardial infarction: safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI)-9a trial. Circulation. 1994;90:1624-1630.
44. Topol E, Califf R, Vandewerf F, Ardissino D, Armstrong P, Aylward P, Barbash G, Bates E, Beatt K, Betriu A, Chesebro J, Col J, Ellis S, Emanuelsson H, Fuster V, Gibler W, Gore J, Guerci A, Hochman J, Holmes D, Kleiman N, Morris D, Neuhaus K, Ohman M, Pfisterer M, Phillips H, Rutsch W, Simes J, Simoons M, Vahanian A, Weaver D, White H. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation. 1994;90:1631-1637.